Genmab — Oktober 2024
-
Kiggede af nysgerrighed lige på Genmabs patent. det hedder, at det dækker"include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion."
-
US7829673B2 - Antibodies against CD38 for treatment of multiple myeloma - Google Patents
Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
(patents.google.com)
-
Er Genmab alt for billig? https://aktietip.dk/er-genmab-alt-for-billig/
-
Stockbull now writing for Zacks/Yahoo?? - -
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround https://finance.yahoo.com/news/down-14-68-4-weeks-133506234.html -
IJGC podcast - Dr. Ignace Vergote to discuss Tisotumab Vidotin in Second- & Third-Line Recurrent Cervical https://open.spotify.com/episode/2YiCmRc3LC9soPRHt0g5nR
-
Hemab Therapeutics is actively enrolling a Phase 2 clinical trial of HMB-001, a subcutaneous injection designed to restore clot formation impaired by GT https://x.com/Hemab_Tx/status/1843973949782475135
-
Zacks Estimate Q3 24 For Darzalex, the consensus as well as our model estimates is pegged at $2.94 billion. https://ca.finance.yahoo.com/news/jnj-stock-portfolio-ahead-q3-190000402.html
-
small
new trial for Amivantamab in Malignant Brain Tumours (5G-EMERALD) https://clinicaltrials.gov/study/NCT06632236 -
Halozymes er faldet kraftigt på det seneste https://finance.yahoo.com/quote/HALO/ Ingen nyheder direkte relateret til Halo. Men er der udvikling i forventningerne til, hvorvidt den teknologi de tilfører stofferne rammes af patentproblemer eller prisforhandlinger på blandingsproduktet, hvor begge stoffer går af patent ? Dara og halos stof går f. eks. begge af patent i US i hhv 2029 og 2027. Herefter er det i princippet to ikke patenterede stoffer der blot blandes til faspro.
-
https://www.hhs.gov/about/news/2024/09/30/hhs-announces-cost-savings-for-prescription-drugs-thanks-to-medicare-inflation-rebate-program.html Det kræver lidt mere energi end jeg har i dag for at sætte sig ind i dette. Og så ved jeg egentligt ikke om det er dette program der truer faspro ?
-
Tjaaaa... @gdn55 . Men a
-
antallet af hår på dit hoved at vel faldet tilsvarende. Hvad er er sket over de seneste 13 år, er, i min opfattelse, totalt ligegyldigt. Når jeg ser på min portefølje er det dagens værdi - og fremtidens muligheder
-
og - jeg beklager - der står Genmab, i min opfattelse, ikke nr. 1 på min hitliste
-
Det er jeg da kun glad for - men, jeg ser altså bare mere på mulighederne, end fortidens forfald. Min DSV position har, med mega stor fart, overhalet min Genmab position. Men, hver sin fornøjelse - jeg kan bedst lige fremrettede muligheder
-
lide
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind